Feng Jiang1, Min Teng2, Yan-Xin Zhu3, Yong-Jie Li4. 1. Department of Physical and Chemical Inspection, Wen Ling Institute For Food and Drug Control, Taizhou, China. 2. Public Health Section, Chengdu Shuangliu District Maternal and Child Health Hospital, Chengdu, China. 3. Department of Laboratory, Guizhou Orthopedics Hospital, Guiyang, China. 4. School of Pharmacy, Shaoyang University, Shaoyang, China.
Abstract
BACKGROUND: The relationship between dietary acrylamide intake and renal cell carcinoma risk is inconclusive. In consideration of the recent findings, we conducted an updated meta-analysis to assess the association between acrylamide intake and renal cell carcinoma risk. RESULTS: PubMed, EMBASE, and Cochrane databases have been used to identify epidemiological studies on dietary acrylamide intake and renal cell carcinoma risk. This meta-analysis study included eight studies, 2843 cases, and 309 920 controls/participants. We performed meta-analyses to calculate the summary relative risk (RR) for the highest versus lowest intake of dietary acrylamide. No meaningful association was found for renal cell carcinoma; RR was 1.12 (95% confidence interval (CI): 0.97-1.28). Among participants who never smoked, no association was found between dietary acrylamide and renal cell carcinoma; the RR for highest versus lowest intake of dietary acrylamide was 1.11 (95% CI: 0.93-1.32). CONCLUSION: This meta-analysis study indicates that dietary acrylamide is not related to the risk of renal cell carcinoma.
BACKGROUND: The relationship between dietary acrylamide intake and renal cell carcinoma risk is inconclusive. In consideration of the recent findings, we conducted an updated meta-analysis to assess the association between acrylamide intake and renal cell carcinoma risk. RESULTS: PubMed, EMBASE, and Cochrane databases have been used to identify epidemiological studies on dietary acrylamide intake and renal cell carcinoma risk. This meta-analysis study included eight studies, 2843 cases, and 309 920 controls/participants. We performed meta-analyses to calculate the summary relative risk (RR) for the highest versus lowest intake of dietary acrylamide. No meaningful association was found for renal cell carcinoma; RR was 1.12 (95% confidence interval (CI): 0.97-1.28). Among participants who never smoked, no association was found between dietary acrylamide and renal cell carcinoma; the RR for highest versus lowest intake of dietary acrylamide was 1.11 (95% CI: 0.93-1.32). CONCLUSION: This meta-analysis study indicates that dietary acrylamide is not related to the risk of renal cell carcinoma.